None listed
Conditions
Brief summary
Non-steroidal anti-inflammatory drugs (NSAIDs) are a common cause of renal damage. The risk of renal injury dramatically increases when NSAIDs are taken together with angiotensin-converting enzyme inhibitors (ACEi) or angiotensin II receptor blockers (ARBs) plus a diuretic– this is known as the “triple whammy” combination. Co-prescribing of these medications is still common in New Zealand, and patients can easily buy NSAIDs independently of their doctor. Providing information directly to patients may help address some of those issues. We have developed patient educational material including a printable information sheet, a webpage and an online learning activity with collaborative input from patients, GPs, pharmacists, and a patient education provider. These resources aim to inform patients about their elevated risk of harm from NSAIDs, and discourage them from using over-the-counter NSAIDs. We have tested this material in a feasibility trial (ACTRN12621000574842). A randomised controlled trial is now planned to examine the effect of giving patients at-risk harm from the “triple whammy” (because of the combination of long-term medications they are prescribed) this information directly, without needing their health care practitioners to provide it.
Interventions
Intervention group patients will be emailed a link to a webpage containing a downloadable PDF and a fully accessible online interactive learning activity. Both the PDF and interactive learning activity have been designed specifically for this project. The single A4 page PDF provides background information about the potential drug interactions and effect on the kidneys, as well as advice about avoiding non-steroidal anti-inflammatory medication. Participants can download and print this information if they would like. The interactive learning activity provides more detailed information about the potential harms associated with non-steroidal anti-inflammatory medication, and potential drug interactions. There are self-marking quizzes to reinforce learning for each short module. Participants will complete 4 modules in the online learning activity, which takes about 10-15 minutes to complete in total. Participants can access the online learning activity as many times as they like during the two week study period. Administration of the intervention will occur by automatic email at time of randomisation. Use of the intervention will be assessed by self-report in the follow-up survey. The intervention group will also receive usual general practice care from their own primary care team. Usual general practice care means patients can contact their general practice as often as they like during normal business hours to speak with a healthcare provider, have a clinical appointment, receive advice or any clinical treatment deemed necessary, or be referred on for secondary care if required.
Sponsors
Study design
Eligibility
Inclusion criteria
1. Must be prescribed an angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers, PLUS a diuretic in the past 3 months 2. Must be a registered patient at a general practice in Aotearoa New Zealand 3. Have signed up to receive emails from Conporto Health Ltd
Exclusion criteria
1. Do not take the prerequisite medication 2. Do not complete the consent process